Bracco's SonoRx Is First Oral Contrast Agent For Upper Abdominal Imaging
This article was originally published in The Gray Sheet
Executive Summary
Bracco Diagnostics' SonoRx, the first oral contrast agent for ultrasound imaging, will be available by the end of the year, the company said following its Oct. 29 FDA approval. SonoRx is intended to reduce gas shadowing during upper abdominal ultrasound procedures, a problem that can obscure the radiologist's view regardless of the type of ultrasound equipment used.